Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude Agrees To Pay $39m To Settle Shareholder Suit

Executive Summary

The settlement, which does not include an admission of fault, puts an end to a long-running class action claim filed by investors who say they were misled by St. Jude’s failure to announce FDA safety concerns around the company’s Durata heart leads.

You may also be interested in...

HRS 2018 Wrap-Up: Tendril Lead Failures; Metaanalysis Of Contact-Force Catheter; LuxCath's OmniView; More Micra Results

The 2018 Heart Rhythm Society scientific sessions in Boston covered a variety of presentations of new electrophysiology clinical data, including a report on the failure of St. Jude's Tendril leads, a meta-analysis of contact-force catheters for atrial-fibrillation ablation, and new data on Medtronic's Micra leadless pacemaker.

The Rumors Were True: Abbott Buys St. Jude For $25b To Create Third Cardiovascular Giant

Abbott Laboratories has agreed to acquire St. Jude Medical for $25bn, creating a third player, along with Boston Scientific and Medtronic, that competes in all major sectors of the cardiovascular device business.

Another St. Jude ICD Lead Recall, But Impact May Be Limited

The recall, related to a manufacturing misstep for St. Jude's Optisure defibrillator leads, effects 447 devices and has not been linked to any patient injuries, the firm says.

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts